Luis Palomera

3.1k total citations
30 papers, 903 citations indexed

About

Luis Palomera is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Luis Palomera has authored 30 papers receiving a total of 903 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 15 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Luis Palomera's work include Multiple Myeloma Research and Treatments (15 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Protein Degradation and Inhibitors (7 papers). Luis Palomera is often cited by papers focused on Multiple Myeloma Research and Treatments (15 papers), Chronic Lymphocytic Leukemia Research (7 papers) and Protein Degradation and Inhibitors (7 papers). Luis Palomera collaborates with scholars based in Spain, France and United States. Luis Palomera's co-authors include Jesús F. San Miguel, Albert Oriol, Juan José Lahuerta, Felipe de Arriba, Joan Bladé, Joan Bargay, Miguel‐Teodoro Hernández, María‐Victoria Mateos, Pilar Giraldo and Javier de la Rubia and has published in prestigious journals such as New England Journal of Medicine, Blood and Scientific Reports.

In The Last Decade

Luis Palomera

29 papers receiving 893 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luis Palomera Spain 14 634 500 421 179 170 30 903
Abdul Hamid Bazarbachi United States 14 550 0.9× 388 0.8× 479 1.1× 153 0.9× 107 0.6× 30 878
Sherilyn A. Tuazon United States 10 517 0.8× 476 1.0× 494 1.2× 128 0.7× 92 0.5× 27 941
Khalid Mezzi United States 12 499 0.8× 411 0.8× 426 1.0× 142 0.8× 68 0.4× 26 788
Caitlin Costello United States 17 455 0.7× 463 0.9× 519 1.2× 157 0.9× 80 0.5× 64 910
Sophie Derenne France 8 338 0.5× 418 0.8× 362 0.9× 159 0.9× 59 0.3× 11 780
Jaime Bald United States 8 639 1.0× 339 0.7× 499 1.2× 258 1.4× 149 0.9× 10 903
Jakub Krejcik Denmark 10 795 1.3× 449 0.9× 593 1.4× 322 1.8× 172 1.0× 13 1.1k
Edward Allan R. Sison United States 11 844 1.3× 1.5k 3.0× 403 1.0× 220 1.2× 93 0.5× 22 1.9k
Sandy W. Wong United States 20 583 0.9× 593 1.2× 683 1.6× 164 0.9× 108 0.6× 86 1.1k
B. Emmerich Germany 14 360 0.6× 254 0.5× 183 0.4× 286 1.6× 220 1.3× 39 733

Countries citing papers authored by Luis Palomera

Since Specialization
Citations

This map shows the geographic impact of Luis Palomera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis Palomera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis Palomera more than expected).

Fields of papers citing papers by Luis Palomera

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luis Palomera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis Palomera. The network helps show where Luis Palomera may publish in the future.

Co-authorship network of co-authors of Luis Palomera

This figure shows the co-authorship network connecting the top 25 collaborators of Luis Palomera. A scholar is included among the top collaborators of Luis Palomera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luis Palomera. Luis Palomera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cuenca, Marta, Alfonso Serrano del Valle, Gemma Azaceta, et al.. (2023). Dinaciclib synergizes with BH3 mimetics targeting BCL‐2 and BCL‐XL in multiple myeloma cell lines partially dependent on MCL‐1 and in plasma cells from patients. Molecular Oncology. 17(12). 2507–2525. 2 indexed citations
2.
Mateos, María‐Victoria, Miguel‐Teodoro Hernández, Javier de la Rubia, et al.. (2022). Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study. European Journal of Cancer. 174. 243–250. 19 indexed citations
3.
Martı́nez, Carmen, Cecilia Carpio, Inmaculada Heras, et al.. (2020). Potential Survival Benefit for Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation after Nivolumab Therapy for Relapse/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain. Biology of Blood and Marrow Transplantation. 26(8). 1534–1542. 18 indexed citations
4.
Reina-Ortiz, Chantal, Maria Rita Polo Gascón, Daniel Woods, et al.. (2020). Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance. Scientific Reports. 10(1). 19398–19398. 24 indexed citations
5.
Reina-Ortiz, Chantal, Michael G. Constantinides, Jessy Présumey, et al.. (2020). Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients. OncoImmunology. 10(1). 1853314–1853314. 28 indexed citations
6.
7.
Steegmann, Juan Luis, Dolors Colomer, María Teresa Gómez‐Casares, et al.. (2017). An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase. Journal of Cancer Research and Clinical Oncology. 143(10). 2059–2066. 2 indexed citations
8.
Mateos, María‐Victoria, Miguel‐Teodoro Hernández, Pilar Giraldo, et al.. (2016). Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. The Lancet Oncology. 17(8). 1127–1136. 107 indexed citations
9.
Sánchez‐Martínez, Diego, Pilar M. Lanuza, Natalia Gómez, et al.. (2016). Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells. Frontiers in Immunology. 7. 454–454. 25 indexed citations
10.
Sánchez‐Martínez, Diego, Gemma Azaceta, Aura Muntasell, et al.. (2015). Human NK cells activated by EBV+lymphoblastoid cells overcome anti-apoptotic mechanisms of drug resistance in haematological cancer cells. OncoImmunology. 4(3). e991613–e991613. 38 indexed citations
11.
12.
13.
Mateos, María‐Victoria, Miguel‐Teodoro Hernández, Pilar Giraldo, et al.. (2013). Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine. 369(5). 438–447. 348 indexed citations
14.
Galán‐Malo, Patricia, Ariel Ramírez-Labrada, Marta Pérez-Hernández, et al.. (2013). Granulysin induces apoptotic cell death and cleavage of the autophagy regulator Atg5 in human hematological tumors. Biochemical Pharmacology. 87(3). 410–423. 29 indexed citations
15.
García‐Sánz, Ramón, Albert Oriol, Javier de la Rubia, et al.. (2012). Analysis of Zoledronic ACID Therapy for Patients with Multiple Myeloma with Asymptomatic Biochemical Relaps.. Blood. 120(21). 2967–2967. 1 indexed citations
16.
Vela, Laura, Marı́a Contel, Luis Palomera, Gemma Azaceta, & Isabel Marzo. (2011). Iminophosphorane–organogold(III) complexes induce cell death through mitochondrial ROS production. Journal of Inorganic Biochemistry. 105(10). 1306–1313. 52 indexed citations
17.
Alegre, Adrían, Beatriz Aguado, Pilar Giraldo, et al.. (2011). Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. International Journal of Hematology. 93(3). 351–360. 15 indexed citations
18.
19.
Miguel, Jesús F. San, Júlia Almeida, Gema Mateo, et al.. (2002). Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood. 99(5). 1853–1856. 99 indexed citations
20.
Palomera, Luis, et al.. (2000). Rotura espontánea de bazo por peliosis esplénica en una paciente con púrpura trombocitopénica autoinmune tratada con danazol. Medicina Clínica. 114(19). 759–759. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Abdul Hamid Bazarbachi Breakdown of academic impact, for papers by Sherilyn A. Tuazon Breakdown of academic impact, for papers by Khalid Mezzi Breakdown of academic impact, for papers by Caitlin Costello Breakdown of academic impact, for papers by Sophie Derenne Breakdown of academic impact, for papers by Jaime Bald Breakdown of academic impact, for papers by Jakub Krejcik Breakdown of academic impact, for papers by Edward Allan R. Sison Breakdown of academic impact, for papers by Sandy W. Wong Breakdown of academic impact, for papers by B. Emmerich
Rankless by CCL
2026